Molecular Markers in ALL: Clinical Implications

Overview

Journal Best Pract Res Clin Haematol

Publisher Elsevier

Specialty Hematology

Date 2020 Oct 11

PMID 33038982

Citations 22

Authors

Shunsuke Kimura

Charles G Mullighan

Affiliations

Soon will be listed here.

Abstract

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and remains a main cause of death in children despite recent improvements in cure rates. In the past decade, development of massively parallel sequencing has enabled large scale genome profiling studies of ALL, which not only led to identification of new subtypes in both B-cell precursor ALL (BCP-ALL) and T-cell ALL (T-ALL), but has also identified potential new therapeutic approaches to target vulnerabilities of many subtypes. Several of these approaches have been validated in preclinical models and are now being formally evaluated in prospective clinical trials. In this review, we provide an overview of the recent advances in our knowledge of genomic bases of BCP-ALL, T-ALL, and relapsed ALL, and discuss their clinical implications.

Citing Articles

Advances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia.

Sucre O, Pamulapati S, Muzammil Z, Bitran J Cells. 2025; 14(5).

PMID: 40072099 PMC: 11898990. DOI: 10.3390/cells14050371.

Aptamer sgc8-Modified PAMAM Nanoparticles for Targeted siRNA Delivery to Inhibit BCL11B in T-Cell Acute Lymphoblastic Leukemia.

Zeng X, Nie D, Liu Z, Peng X, Wang X, Qiu K Int J Nanomedicine. 2024; 19:12297-12309.

PMID: 39583320 PMC: 11585994. DOI: 10.2147/IJN.S477597.

Molecular insights into the hedgehog signaling pathway correlated non-coding RNAs in acute lymphoblastic leukemia, a bioinformatics study.

Talebi E, Ghoraeian P, Shams Z, Rahimi H Ann Hematol. 2024; 103(12):5439-5447.

PMID: 39223285 DOI: 10.1007/s00277-024-05763-3.

TCF3 as a multidimensional biomarker: oncogenicity, genomic alterations, and immune landscape in pan-cancer analysis.

Nie H, Yu Y, Zhou S, Xu Y, Chen X, Qin X Acta Biochim Biophys Sin (Shanghai). 2024; 57(2):195-208.

PMID: 39205642 PMC: 11868920. DOI: 10.3724/abbs.2024126.

Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.

Neumann M, Beder T, Bastian L, Hanzelmann S, Bultmann M, Wolgast N Leukemia. 2024; 38(6):1213-1222.

PMID: 38744920 PMC: 11147771. DOI: 10.1038/s41375-024-02264-0.

References

French C . NUT midline carcinoma. Nat Rev Cancer. 2015; 14(3):149-50. DOI: 10.1038/nrc3659. View

Ferrando A, Neuberg D, Staunton J, Loh M, Huard C, Raimondi S . Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002; 1(1):75-87. DOI: 10.1016/s1535-6108(02)00018-1. View

Hirabayashi S, Ohki K, Nakabayashi K, Ichikawa H, Momozawa Y, Okamura K . ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica. 2016; 102(1):118-129. PMC: 5210242. DOI: 10.3324/haematol.2016.151035. View

Papaemmanuil E, Rapado I, Li Y, Potter N, Wedge D, Tubio J . RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014; 46(2):116-25. PMC: 3960636. DOI: 10.1038/ng.2874. View

Gianni F, Belver L, Ferrando A . The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia. Cold Spring Harb Perspect Med. 2019; 10(3). PMC: 7050584. DOI: 10.1101/cshperspect.a035246. View

Chang B, Willis S, Stork L, Hunger S, Carroll W, Camitta B . Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. Br J Haematol. 2012; 157(4):507-10. PMC: 4290865. DOI: 10.1111/j.1365-2141.2012.09039.x. View

Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman M . Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016; 48(12):1481-1489. PMC: 5144107. DOI: 10.1038/ng.3691. View

Zaliova M, Potuckova E, Hovorkova L, Musilova A, Winkowska L, Fiser K . deletions in childhood acute lymphoblastic leukemia with rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity. Haematologica. 2019; 104(7):1407-1416. PMC: 6601096. DOI: 10.3324/haematol.2018.204487. View

Duque-Afonso J, Feng J, Scherer F, Lin C, Wong S, Wang Z . Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia. J Clin Invest. 2015; 125(9):3667-80. PMC: 4588292. DOI: 10.1172/JCI81158. View

10.

Weng A, Ferrando A, Lee W, Morris 4th J, Silverman L, Sanchez-Irizarry C . Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-71. DOI: 10.1126/science.1102160. View

11.

Mullighan C, Miller C, Radtke I, Phillips L, Dalton J, Ma J . BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008; 453(7191):110-4. DOI: 10.1038/nature06866. View

12.

Lilljebjorn H, Henningsson R, Hyrenius-Wittsten A, Olsson L, Orsmark-Pietras C, von Palffy S . Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016; 7:11790. PMC: 4897744. DOI: 10.1038/ncomms11790. View

13.

Pfeifer H, Cazzaniga G, van der Velden V, Cayuela J, Schafer B, Spinelli O . Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. 2019; 33(8):1910-1922. DOI: 10.1038/s41375-019-0413-0. View

14.

Suzuki K, Okuno Y, Kawashima N, Muramatsu H, Okuno T, Wang X . MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents. J Clin Oncol. 2016; 34(28):3451-9. DOI: 10.1200/JCO.2016.66.5547. View

15.

Tanasi I, Ba I, Sirvent N, Braun T, Cuccuini W, Ballerini P . Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood. 2019; 134(16):1351-1355. DOI: 10.1182/blood.2019001244. View

16.

Passet M, Boissel N, Sigaux F, Saillard C, Bargetzi M, Ba I . P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood. 2018; 133(3):280-284. DOI: 10.1182/blood-2018-10-882142. View

17.

Sundaresh A, Williams O . Mechanism of ETV6-RUNX1 Leukemia. Adv Exp Med Biol. 2017; 962:201-216. DOI: 10.1007/978-981-10-3233-2_13. View

18.

Hovorkova L, Zaliova M, Venn N, Bleckmann K, Trkova M, Potuckova E . Monitoring of childhood ALL using genomic breakpoints identifies a subgroup with CML-like biology. Blood. 2017; 129(20):2771-2781. DOI: 10.1182/blood-2016-11-749978. View

19.

Valentine M, Linabery A, Chasnoff S, Hughes A, Mallaney C, Sanchez N . Excess congenital non-synonymous variation in leukemia-associated genes in MLL- infant leukemia: a Children's Oncology Group report. Leukemia. 2013; 28(6):1235-41. PMC: 4045651. DOI: 10.1038/leu.2013.367. View

20.

Real P, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E . Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2008; 15(1):50-8. PMC: 2692090. DOI: 10.1038/nm.1900. View